Vertex Pharmaceuticals traded at $281.79 this Thursday June 30th, increasing $1.44 or 0.51 percent since the previous trading session. Looking back, over the last four weeks, Vertex Pharmaceuticals gained 4.89 percent. Over the last 12 months, its price rose by 39.36 percent. Looking ahead, we forecast Vertex Pharmaceuticals to be priced at 284.68 by the end of this quarter and at 262.32 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
281.79
Daily Change
0.51%
Yearly
39.36%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 153.16 -0.98 -0.64% 34.05%
Acadia Pharmaceuticals 14.09 -0.13 -0.91% -43.12%
Acorda Therapeutics 0.47 0.02 4.25% -89.92%
Agios Pharmaceuticals 22.17 -0.21 -0.94% -60.71%
Alnylam Pharmaceuticals 145.85 0.42 0.29% -14.08%
Amgen 243.30 -2.13 -0.87% -1.46%
Arrowhead Research 35.21 0.65 1.88% -58.56%
Biogen 203.94 -1.29 -0.63% -41.55%
Bluebird Bio 4.14 -0.44 -9.61% -87.23%
BioMarin Pharmaceutical 82.87 -1.05 -1.25% -1.24%
Bristol-Myers Squibb 77.00 -1.28 -1.64% 15.69%
Gilead Sciences 61.81 -0.67 -1.07% -10.59%
Intercept Pharmaceuticals 13.81 0.14 1.02% -32.54%
Incyte Corp 75.97 0.08 0.11% -9.58%
Insmed 19.72 -0.35 -1.74% -33.08%
Ionis Pharmaceuticals 37.02 -0.54 -1.44% -7.57%
J&J 177.51 0.52 0.29% 6.96%
Merck & Co 91.17 -1.34 -1.45% 16.90%
Moderna Inc 142.85 0.04 0.03% -39.24%
Neurocrine Biosciences 97.48 -0.98 -1.00% 0.02%
Novartis 80.85 -0.34 -0.42% -4.23%
Puma Biotechnology 2.85 0 0% -69.65%
Pfizer 52.43 1.49 2.93% 32.53%
PTC Therapeutics 40.06 -0.34 -0.84% -8.46%
Ultragenyx Pharmaceutical 59.66 -0.58 -0.96% -36.61%
Regeneron Pharmaceuticals 591.13 -6.49 -1.09% 2.87%
Roche Holding 318.55 -1.10 -0.34% -9.02%
Sanofi 96.34 -4.54 -4.50% 8.91%
Seattle Genetics 176.94 -2.12 -1.18% 11.80%
Sangamo BioSciences 4.14 0 0% -65.53%
Sarepta Therapeutics 74.96 -2.11 -2.74% -4.23%
United Therapeutics 235.64 -2.65 -1.11% 27.60%
Vertex Pharmaceuticals 281.79 1.44 0.51% 39.36%

Indexes Price Day Year
US500 3777 -33.45 -0.88% -12.57%
USND 11029 -149.16 -1.33% -24.06%
US400 2269 -21.75 -0.95% -16.49%
USNDX 11497 -154.55 -1.33% -21.04%

Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.